Staff Profile: Andre Pilon

Andre M. Pilon, Ph.D.

Program Manager

Division of Preclinical Innovation
Therapeutics for Rare and Neglected Diseases (Contractor)

National Center for Advancing Translational Sciences

National Institutes of Health

Email Andre M. Pilon


Andre M. Pilon is a program manager in NCATS’ Division of Preclinical Innovation, where he works on the portfolio management and strategic operations team that manages the Center’s Therapeutics for Rare and Neglected Diseases (TRND) program, a diverse and highly collaborative research and development effort. Pilon completed doctoral and postdoctoral research on the molecular underpinnings of red blood cell development and disorders at the National Human Genome Research Institute (NHGRI) under the mentorship of David M. Bodine, Ph.D. Before joining TRND, Pilon served as a policy and education fellow with detail appointments in the NHGRI Office of Policy, Communications and Education; the American Society of Human Genetics; the American Association for Cancer Research; and the NIH Office of Legislative Policy and Analysis.

Pilon received a B.A. in chemistry-biochemistry from Colby College and a Ph.D. in biochemistry and molecular genetics from the George Washington University Medical Center, where he participated in a joint research program with NIH.

Professional Interests

Pilon is an enthusiastic communicator. His work involves helping diverse audiences of fellow researchers, policymakers, business leaders and the public understand NCATS’ exceptional research programs. He manages the solicitation of collaborative projects for TRND and develops outreach and communications messages. Pilon is keenly interested in implementing operational efficiency. He continuously seeks to develop and refine strategies to solicit, evaluate and initiate new collaborative research opportunities, including identifying potential synergies with other NCATS and NIH programs.

Selected Publications

  1. Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism
  2. NIH TRND program: successes in preclinical therapeutic development